Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Reports Third Quarter 2017 Financial Results
Phase 3 FORT Study of fosmetpantotenate continues to enroll PKAN patients Third quarter revenues increased 19 percent to $40 million SAN DIEGO, CALIFORNIA -- (Marketwired) -- 11/07/17 -- Retrophin, Inc. (NASDAQ:RTRX) today reported its third quarter 2017 financial results and provided a corporate
View HTML
Toggle Summary Retrophin Reports Additional Positive Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
Progressive reduction in proteinuria and stable eGFR observed in open-label treatment period   Findings presented at ASN Kidney Week 2017 SAN DIEGO , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced new positive data from the ongoing open-label extension of the Phase
View HTML
Toggle Summary Retrophin to Present at the Jefferies 2017 London Healthcare Conference
SAN DIEGO , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Jefferies 2017 London Healthcare Conference in London, UK on Thursday, November 16, 2017 at 1:20 p.m. GMT ( 8:20 a.m. ET ).
View HTML
Toggle Summary Retrophin to Report Third Quarter 2017 Financial Results
SAN DIEGO , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report third quarter 2017 financial results on Tuesday, November 7, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin to Present New Data for Sparsentan at ASN Kidney Week 2017
SAN DIEGO , Oct. 13, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that it will present new data from the open label extension portion of the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, at the
View HTML
Toggle Summary Retrophin Announces Presentation of New Data from Physician-Initiated Treatment with Fosmetpantotenate at the Child Neurology Society’s 26th Annual Meeting
Patient with PKAN showed persistent improvement in function over 30-month period of treatment with fosmetpantotenate SAN DIEGO , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the presentation of new data from physician-initiated treatment with fosmetpantotenate
View HTML
Toggle Summary Retrophin to Present at September Investor Conferences
SAN DIEGO , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at two upcoming investor conferences in New York City , including: Cantor Fitzgerald Global Healthcare Conference Date: Monday, September 25,
View HTML
Toggle Summary Retrophin Announces Cooperative Research and Development Agreement with NCATS and NGLY1.org to Identify Potential Small Molecule Therapeutics for NGLY1 Deficiency
SAN DIEGO , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient
View HTML
Toggle Summary Retrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that its Compensation Committee granted inducement awards pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules on July 31, 2017 , August 7, 2017 and August 14, 2017 consisting of stock options to purchase
View HTML
Toggle Summary Retrophin Reports Second Quarter 2017 Financial Results
Fosmetpantotenate (RE-024) Phase 3 trial underway in PKAN Protocol design for pivotal Phase 3 trial of sparsentan in FSGS complete; sparsentan IP estate expanded to 2030 for FSGS Second quarter revenues increased 16 percent to $39 million SAN DIEGO , Aug.
View HTML